09/28/2006
Gamida Cell raised $16 million in a financing round led by Israel Healthcare Ventures
Gamida Cell has raised $16 million in a financing round led by Israel Healthcare Ventures (IHCV). Current shareholders Elscint Biomedical Investment, Denali Ventures, Biomedical Investments and TEVA Pharmaceuticals also participated.
The capital will support three major initiatives: the expansion of Gamida Cell’s tissue regeneration product pipeline, including the cardiac regeneration product, now at the advanced pre-clinical stage of development; the planned clinical testing of the company’s flagship product StemEx for indications; and, the ongoing pre-clinical development of products for conditions such as neurological disorders and peripheral vascular disease.
“The clinical results of the Phase I/II study of StemEx as a treatment for leukemia and lymphoma were extremely favorable,” said Dr. Yael Margolin, Gamida Cell president and CEO. “We plan to begin a global, pivotal study of StemEx in the very near future to demonstrate the efficacy of the product. Assuming smooth sailing, we plan to bring it to market in 2009 in partnership with TEVA.”
Gamida Cell is developing a line of cell therapy products for the treatment of debilitating and fatal diseases with unmet clinical needs. StemEx, Gamida Cell's product in advanced clinical development for the treatment of hematological diseases, is being developed in a Joint Venture with Teva Pharmaceuticals. The Jerusalem based drug discovery firm has an additional product in advanced pre-clinical development for the treatment of heart disease.
Israel Science Technology Blog Ad – Lower Back Pain Treatment | Candida Yeast Infection Test Kit
08:25 Posted in Drug Discovery | Permalink | Comments (0) | Email this | Tags: leukemia, lymphoma, Gamida Cell, Israel Healthcare Ventures, Elscint, Denali Ventures, Biomedical Investments